345 related articles for article (PubMed ID: 28912847)
1. Identification of microRNAs involved in gefitinib resistance of non-small-cell lung cancer through the insulin-like growth factor receptor 1 signaling pathway.
Ma W; Kang Y; Ning L; Tan J; Wang H; Ying Y
Exp Ther Med; 2017 Oct; 14(4):2853-2862. PubMed ID: 28912847
[TBL] [Abstract][Full Text] [Related]
2. miR-497 may enhance the sensitivity of non-small cell lung cancer cells to gefitinib through targeting the insulin-like growth factor-1 receptor.
Ma W; Feng W; Tan J; Xu A; Hu Y; Ning L; Kang Y; Wang L; Zhao Z
J Thorac Dis; 2018 Oct; 10(10):5889-5897. PubMed ID: 30505497
[TBL] [Abstract][Full Text] [Related]
3. The long non-coding RNA, GAS5, enhances gefitinib-induced cell death in innate EGFR tyrosine kinase inhibitor-resistant lung adenocarcinoma cells with wide-type EGFR via downregulation of the IGF-1R expression.
Dong S; Qu X; Li W; Zhong X; Li P; Yang S; Chen X; Shao M; Zhang L
J Hematol Oncol; 2015 Apr; 8():43. PubMed ID: 25925741
[TBL] [Abstract][Full Text] [Related]
4. MiR-30a-5p Overexpression May Overcome EGFR-Inhibitor Resistance through Regulating PI3K/AKT Signaling Pathway in Non-small Cell Lung Cancer Cell Lines.
Meng F; Wang F; Wang L; Wong SC; Cho WC; Chan LW
Front Genet; 2016; 7():197. PubMed ID: 27895663
[TBL] [Abstract][Full Text] [Related]
5. Identification of potential microRNAs and their targets in promoting gefitinib resistance by integrative network analysis.
Zheng F; Zhang H; Lu J
J Thorac Dis; 2019 Dec; 11(12):5535-5546. PubMed ID: 32030273
[TBL] [Abstract][Full Text] [Related]
6. Reduced expression of EI24 confers resistance to gefitinib through IGF-1R signaling in PC9 NSCLC cells.
Choi JM; Jang JY; Choi YR; Kim HR; Cho BC; Lee HW
Lung Cancer; 2015 Nov; 90(2):175-81. PubMed ID: 26342551
[TBL] [Abstract][Full Text] [Related]
7. Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations.
Yeo CD; Park KH; Park CK; Lee SH; Kim SJ; Yoon HK; Lee YS; Lee EJ; Lee KY; Kim TJ
Lung Cancer; 2015 Mar; 87(3):311-7. PubMed ID: 25617986
[TBL] [Abstract][Full Text] [Related]
8. Combined treatment with metformin and gefitinib overcomes primary resistance to EGFR-TKIs with EGFR mutation via targeting IGF-1R signaling pathway.
Pan YH; Jiao L; Lin CY; Lu CH; Li L; Chen HY; Wang YB; He Y
Biologics; 2018; 12():75-86. PubMed ID: 30154647
[TBL] [Abstract][Full Text] [Related]
9. miR-138-5p reverses gefitinib resistance in non-small cell lung cancer cells via negatively regulating G protein-coupled receptor 124.
Gao Y; Fan X; Li W; Ping W; Deng Y; Fu X
Biochem Biophys Res Commun; 2014 Mar; 446(1):179-86. PubMed ID: 24582749
[TBL] [Abstract][Full Text] [Related]
10. miR-223 enhances the sensitivity of non-small cell lung cancer cells to erlotinib by targeting the insulin-like growth factor-1 receptor.
Zhao FY; Han J; Chen XW; Wang J; Wang XD; Sun JG; Chen ZT
Int J Mol Med; 2016 Jul; 38(1):183-91. PubMed ID: 27177336
[TBL] [Abstract][Full Text] [Related]
11. Delivery of gefitinib in synergism with thymoquinone
Upadhyay P; Ghosh A; Basu A; Pranati PA; Gupta P; Das S; Sarker S; Bhattacharjee M; Bhattacharya S; Ghosh S; Chattopadhyay S; Adhikary A
Biomater Sci; 2021 Dec; 9(24):8285-8312. PubMed ID: 34766965
[TBL] [Abstract][Full Text] [Related]
12. The relationship between miR-17-5p, miR-92a, and let-7b expression with non-small cell lung cancer targeted drug resistance.
Gong J; He L; Ma J; Zhang J; Wang L; Wang J
J BUON; 2017; 22(2):454-461. PubMed ID: 28534369
[TBL] [Abstract][Full Text] [Related]
13. Inhibiting IGF-1R attenuates cell proliferation and VEGF production in IGF-1R over-expressing EGFR mutant non-small cell lung cancer cells.
Yeo CD; Kim YA; Lee HY; Kim JW; Lee SH; Kim SJ; Kwon SS; Kim YH; Kim SC
Exp Lung Res; 2017 Feb; 43(1):29-37. PubMed ID: 28394654
[TBL] [Abstract][Full Text] [Related]
14. Plasma microRNA alterations between EGFR-activating mutational NSCLC patients with and without primary resistance to TKI.
Ma Y; Pan X; Xu P; Mi Y; Wang W; Wu X; He Q; Liu X; Tang W; An HX
Oncotarget; 2017 Oct; 8(51):88529-88536. PubMed ID: 29179454
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin β3.
Yue J; Lv D; Wang C; Li L; Zhao Q; Chen H; Xu L
Oncogene; 2018 Aug; 37(31):4300-4312. PubMed ID: 29717264
[TBL] [Abstract][Full Text] [Related]
16. Detection of microRNA-200b may predict the inhibitory effect of gefitinib on non-small cell lung cancer and its potential mechanism.
Liu Z; Yao L; Tan B; Li L; Chen B
Oncol Lett; 2016 Dec; 12(6):5349-5355. PubMed ID: 28101246
[TBL] [Abstract][Full Text] [Related]
17. Genome-wide profiling of micro-RNA expression in gefitinib-resistant human lung adenocarcinoma using microarray for the identification of miR-149-5p modulation.
Hu Y; Qin X; Yan D; Cao H; Zhou L; Fan F; Zang J; Ni J; Xu X; Sha H; Liu S; Yu S; Wu J; Ma R; Feng J
Tumour Biol; 2017 Mar; 39(3):1010428317691659. PubMed ID: 28345454
[TBL] [Abstract][Full Text] [Related]
18. Up-regulation of microRNA-503 by high glucose reduces the migration and proliferation but promotes the apoptosis of human umbilical vein endothelial cells by inhibiting the expression of insulin-like growth factor-1 receptor.
Hou LJ; Han JJ; Liu Y
Eur Rev Med Pharmacol Sci; 2018 Jun; 22(11):3515-3523. PubMed ID: 29917206
[TBL] [Abstract][Full Text] [Related]
19. Dysregulated expression of microRNA involved in resistance to osimertinib in
Zhang D; Yang Y; Kang Y; Xie D; Zhang X; Hao J
J Thorac Dis; 2023 Apr; 15(4):1978-1993. PubMed ID: 37197540
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA expression profiles associated with acquired gefitinib-resistance in human lung adenocarcinoma cells.
Ge X; Zheng L; Huang M; Wang Y; Bi F
Mol Med Rep; 2015 Jan; 11(1):333-40. PubMed ID: 25339453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
